Caprostat Injection

Introduction

Caprostat is a medication that contains the active ingredient Epsilon Aminocaproic Acid. It is available in injectable form and is commonly prescribed under the brand name Caprostat.

Uses

Caprostat is primarily used to control and prevent excessive bleeding in patients who have certain medical conditions or have undergone certain surgical procedures. It is commonly used in situations where there is a risk of excessive bleeding, such as during surgeries involving the heart, liver, or prostate gland, as well as in cases of menorrhagia (excessive menstrual bleeding) and traumatic injuries.

Dosage and Administration

The dosage of Caprostat may vary depending on the individual patient and the specific situation. It is typically administered by a healthcare professional, such as a doctor or nurse, in a hospital setting. The exact dosage and frequency of administration will be determined by the healthcare provider based on factors such as the patient’s weight, medical condition, and response to treatment.

Mechanism of Action

Caprostat works by preventing the breakdown of blood clots and promoting clot formation. It does this by inhibiting the activity of plasmin, an enzyme that breaks down clots. By reducing the breakdown of clots, Caprostat helps to control and prevent excessive bleeding.

Side Effects

Common side effects may include nausea, vomiting, diarrhea, and stomach discomfort. These side effects are usually mild and temporary. However, if they persist or become severe. Inform your healthcare provider.

Serious side effects of Caprostat are rare but may include allergic reactions, such as rash, itching, swelling, or difficulty breathing. If you experience any of these symptoms, seek medical attention immediately.

Drug Interactions

Caprostat may interact with certain medications, including anticoagulants (blood thinners) such as warfarin. Inform your healthcare provider about all the medications you are taking, including prescription, over-the-counter, and herbal products, to avoid any potential drug interactions.

Precautions

Before using Caprostat, inform your healthcare provider about any medical conditions you have, especially if you have a history of blood clotting disorders or kidney problems. Mention any medications you are taking, as they may interact with Caprostat.

Caprostat should not be used in individuals who are allergic to Epsilon Aminocaproic Acid or any of the other ingredients in the medication. It is also contraindicated in patients with active intravascular clotting.

Storage

Caprostat should be stored at room temperature, away from direct sunlight and moisture. It should be kept out of the reach of children and pets. Do not freeze the medication.

Patient Tips

• Follow all instructions provided by your healthcare provider regarding the use of Caprostat.
• If you miss a dose, contact your healthcare provider for further instructions.
• Inform your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding, as the use of Caprostat during pregnancy and breastfeeding may not be recommended.
• Keep a record of any side effects you experience and report them to your healthcare provider.
• Do not stop or change the dosage of Caprostat without consulting your healthcare provider.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Isovaleric acidaemia (NHS UK) [Accessed 15 Jun. 2024] (online) Available at:
• Aminocaproic acid (Drugs.com) [Accessed 20 Jun. 2024] (online) Available at:
• Hemophilia (World Federation of Hemophilia) [Accessed 21 Jun. 2024] (online) Available at:
• Riaz O, Aqil A, Asmar S, Vanker R, Hahnel J, Brew C, Grogan R, Radcliffe G. Epsilon-aminocaproic acid versus tranexamic acid in total knee arthroplasty: a meta-analysis study. J Orthop Traumatol. 2019 Jul 18;20(1):28. doi: 10.1186/s10195-019-0534-2. [Accessed 25 Jun. 2024] Available at: